Valeant Pharmaceuticals Announces Collaboration Between Bausch + Lomb And IBM
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Valeant (VRX) Derm NRx Up 2.2% Week-over-Week - RBC Capital
May 6, 2016 8:44 AM EDTRBC Capital analyst Douglas Miehm noted Valeant Pharmaceuticals (NYSE: VRX) Derm NRx increased 2.2% WoW, ophth NRx were up 2.7% WoW, and Addyi NRx were down 16.2% WoW.
"For the week ending April 29th, new derm scripts (NRx) were up 2.2% vs. down 2.9% the prior week," Miehm commented. "NRx this week... More
